What is Lunai Bioworks's market cap?

Lunai Bioworks (LNAI) has a market capitalization of $5.6M and trades on NASDAQ.

Who are Lunai Bioworks's competitors?

Lunai Bioworks's key competitors include Grail, Recursion Pharmaceuticals, Revvity, Inc., and others. These companies compete in similar markets and product categories.

What subsidiaries does Lunai Bioworks have?

Lunai Bioworks's subsidiaries include Renovaro Biosciences, Renovaro Cube, BioSymetrics Inc., and others.

Where is Lunai Bioworks headquartered?

Lunai Bioworks is headquartered in United States of America. It has been publicly traded since 2014.

Lunai Bioworks (LNAI) Stock Fundamentals & Financials

Lunai Bioworks Inc. is a biotechnology and healthcare technology company focused on the convergence of artificial intelligence and advanced cell and gene therapies.

Market cap

$5.58M-80.6%

Earnings

Q1 2026 report

May 15, 2026

Revenue$20.9K EPS-$0.10

Read the full report

Next report

Date not yet announced

Competitors

By market cap

Revvity$17.2B+67.9%

GRAIL, Inc.$6.3B+163%

Recursion Pharmaceuticals, Inc.$2.3B+0.7%

Rezolute$471.0M-37.3%

RenovoRx$57.8M+42.0%

ADV

Advanced Biomed Inc.$8.8M-17.3%

Aclarion, Inc.$6.7M+34.7%

LNA

Lunai Bioworks$5.6M-78.7%

By revenue growth

GRAIL, Inc.+23.1%

Revvity+4.1%

Recursion Pharmaceuticals, Inc.-15.1%

By net margin

Revvity8.16%-2.0pp

GRAIL, Inc.-236.95%+92.9pp

Recursion Pharmaceuticals, Inc.-945.92%+59.0pp

Profile

Lunai Bioworks Inc. is a biotechnology and healthcare technology company focused on the convergence of artificial intelligence and advanced cell and gene therapies. The company leverages proprietary AI platforms to enable early cancer detection, multi-omic biomarker discovery, and the development of allogeneic therapeutic vaccines for solid tumors.

Competitive position

The company differentiates itself through 'Explainable AI' and 'Contingent AI' platforms that offer multi-organ phenotypic screening and differential diagnosis capabilities beyond traditional cellular models.

GeographiesUnited States, United Kingdom, Netherlands, Europe, Middle East

Customer segmentsPharmaceutical Companies, Healthcare Providers, Research Institutions, Payors

Business modelR&D, Enterprise Software, Licensing, Service Laboratory

SuppliersPublic and private genomic databases, Healthy cell donors, Laboratory equipment suppliers, Cloud hosting and networking infrastructure

CustomersOncology clinics, Biopharmaceutical R&D departments, Diagnostic laboratories, Health insurance entities

CountryUnited States of America

Listed2014

CEODavid H. Weinstein

SectorHealthcare

IndustryBiotechnology

Websiterenovarogroup.com

FilingsSEC EDGAR

FAQ

What is Lunai Bioworks's market cap?: Lunai Bioworks (LNAI) has a market capitalization of $5.6M and trades on NASDAQ.
Who are Lunai Bioworks's competitors?: Lunai Bioworks's key competitors include Grail, Recursion Pharmaceuticals, Revvity, Inc., and others. These companies compete in similar markets and product categories.
What subsidiaries does Lunai Bioworks have?: Lunai Bioworks's subsidiaries include Renovaro Biosciences, Renovaro Cube, BioSymetrics Inc., and others.
Where is Lunai Bioworks headquartered?: Lunai Bioworks is headquartered in United States of America. It has been publicly traded since 2014.